<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0"><channel><title><![CDATA[RSS Feed]]></title><description><![CDATA[RSS Feed]]></description><link>http://direct.ecency.com</link><image><url>http://direct.ecency.com/logo512.png</url><title>RSS Feed</title><link>http://direct.ecency.com</link></image><generator>RSS for Node</generator><lastBuildDate>Thu, 14 May 2026 05:59:32 GMT</lastBuildDate><atom:link href="http://direct.ecency.com/created/growthstock/rss.xml" rel="self" type="application/rss+xml"/><item><title><![CDATA[Biofrontera, Opportunities After FDA Approval]]></title><description><![CDATA[Summary Ameluz (nano emulsion) is superior to former formulation Levulan (actinic kreatoses) and Metvix (basal cell carcinoma). FDA approval for Ameluz as treatment for basal cell carcinoma is likely to]]></description><link>http://direct.ecency.com/biotech/@s1241003/biofrontera-opportunities-after-fda-approval</link><guid isPermaLink="true">http://direct.ecency.com/biotech/@s1241003/biofrontera-opportunities-after-fda-approval</guid><category><![CDATA[biotech]]></category><dc:creator><![CDATA[s1241003]]></dc:creator><pubDate>Sun, 29 Apr 2018 11:52:15 GMT</pubDate></item></channel></rss>